On Tuesday, the Vetr crowd downgraded their rating for ACADIA Pharmaceuticals Inc. ACAD from 4.5 stars (Strong Buy) to 3.5 stars (Buy). Crowd sentiment for the stock is mostly positive, with 81 percent of user ratings bullish.
Arcadia saw a few price jumps around the holidays. On Friday, December 23, the stock rose $2 to finish at around $29.75. On Tuesday after the market's holiday break, the stock spiked another dollar before drawing back from both of the gains to end the day shy of $29.
The activity surrounding Acadia's recent moves has to do with promising results on the second phase of study on pimavanserin, an anti-psychotic drug aimed at treating Alzheimer's Disease.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $31.50, which is still well below the average analyst target price of $40.64. Less than 2 percent of Vetr users are holding ACAD in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
